DOCSLIB.ORG

11-Deoxycortisol (Compound S) 17-Hydroxycorticosteroids, 24-Hour

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
11-Deoxycortisol (Compound S) 17-Hydroxycorticosteroids, 24-Hour REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: DEOXYCO11 11-Deoxycortisol (Compound S) Test Number: 3601100 TEST COMPONENTS REV DATE: 07/14/2005 Test Name: Methodology: 11-Deoxycortisol (Compound S) RIA SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 1 mL (0.2) Serum Clot Activator (Red Top, No-Gel) Refrigerated Special An early morning specimen is preferred. Please collect in a Red Non-Gel clot tube. Instructions: GENERAL INFORMATION Testing Schedule: Tues, Thur Expected TAT: 3-4 Days Cpt Code(s): 82634 Order Name: HYDRXY 17 17-Hydroxycorticosteroids, 24-Hour Urine Test Number: 3620750 TEST COMPONENTS REV DATE: 10/02/2009 Test Name: Methodology: 17-Hydroxycorticosteroids, 24-Hour Urine COUL SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 15 mL (5) Urine, 24-hour 24 hour Urine Container Refrigerated Special Collect urine with 10 grams of boric acid to maintain pH below 7.5. Record 24-hour urine volume on test request form and urine vial. Instructions: Random urine samples are acceptable, but reference ranges do not apply. GENERAL INFORMATION Testing Schedule: Mon - Fri Expected TAT: 3-5 Days Cpt Code(s): 83491 COPYRIGHT REGIONAL MEDICAL LABORATORY 2013: VISIT US ONLINE AT: www.rmlonline.com REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: HYDRXPRGS 17-Hydroxyprogesterone Test Number: 3602390 TEST COMPONENTS REV DATE: 01/25/2010 Test Name: Methodology: 17-Hydroxyprogesterone TMS SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 1 mL (0.25) Serum Clot Activator (Red Top, No-Gel) Frozen Alternate 1 mL (0.25) Plasma EDTA (Lavender Top) Frozen 1 mL (0.25) Plasma Lithium Heparin (Dark Green Top / No-GEL) Frozen Special The preferred specimen is Frozen Serum or Plasma. Specimen should be separated from cells ASAP! Instructions: Stability: After separation from cells: Ambient: 48hr; Refrigerated: 1 week; Frozen: 2 years. GENERAL INFORMATION Testing Schedule: Mon, Thu Expected TAT: 2-6 Days Cpt Code(s): 83498 Order Name: KETOSTER17 17-Ketosteroids, 24-Hour Urine Test Number: 3656050 TEST COMPONENTS REV DATE: 04/15/2011 Test Name: Methodology: 17-Ketosteroids, 24-Hour Urine COLO SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 20mL (10mL) Urine, 24-hour 24 hour Urine Container Refrigerated Special Collect urine with 10 grams of boric acid or or 25 mL 50% Acetic Acid or 30 mL 6N HCl during collection to maintain pH below 7.5. Instructions: Keep urine refrigerated during collection and after collection. Record 24-hour urine volume on test request form and urine vial. GENERAL INFORMATION Testing Schedule: Mon - Fri Expected TAT: 2-3 Days Notes: Methodology: Colorimetric with Modified Zimmerman Reaction. Cpt Code(s): 83586 COPYRIGHT REGIONAL MEDICAL LABORATORY 2013: VISIT US ONLINE AT: www.rmlonline.com REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: HYDRXY 18 18-Hydroxycorticosterone Test Number: 2011000 TEST COMPONENTS REV DATE: 05/26/2010 Test Name: Methodology: 18-Hydroxycorticosterone HPLC SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 3mL (1mL) Serum Clot Activator SST (Red/Gray or Tiger Top) Frozen Special Allow to clot then separate and freeze within one hour. Store and ship frozen in plastic vial. Minimum volume does not permit Instructions: repeat analysis. GENERAL INFORMATION Testing Schedule: Monday Expected TAT: 4-9 Days Cpt Code(s): 82542 Order Name: PT PTT AN Abnormal PT/PTT Analyzer Test Number: 1507500 TEST COMPONENTS REV DATE: 11/30/2012 Test Name: Methodology: Abnormal PT/PTT Analyzer SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 46 mL See Instructions See Instructions See Instructions Special Please indicate anticoagulant therapy and submit with specimen or fax "Coagulopathy Questionnaire Form" to 918-744-3236. Instructions: Please collect Twelve 3mL Sodium Citrate 3.2% (Blue Top) tubes and One 10mL Clot tube (Tiger Top) and One 5mL EDTA (Lavender Top). Each Sodium Citrate blue top tube must be filled to the proper level, no hemolysis. Improperly filled tubes can give erroneous results. Whole blood must be transported to lab immediately. If sending citrated plasma aliquots, they must be double spun then aliquot 1.5 ml plasma from each tube into individual plastic aliquot tubes and freeze. Do not pool aliquots together! GENERAL INFORMATION Testing Schedule: Individual Test Dependant Expected TAT: 5-10 Days Clinical Use: This analyzer is designed to evaluate patients with an unexplained prolonged PT or PTT in whom there is no clinical history or strong clinical suspicion of either bleeding or thrombolytic tendency. A pathologist interpretation and patient focused report with summation of test results will be issued with each order. Notes: For more information on this Analyzer, access our "Specialized Tests" section of this guide for a complete listing of tests and CPT codes. Cpt Code(s): See the Test Notes Section of this test. COPYRIGHT REGIONAL MEDICAL LABORATORY 2013: VISIT US ONLINE AT: www.rmlonline.com REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: ABORH ABO Group & Rh Type Test Number: 7301010 TEST COMPONENTS REV DATE: 01/04/2005 Test Name: Methodology: ABO Rh Interpretation HA Anti-A HA Anti-B HA Anti-D HA A1 Cells HA B Cells HA SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 7 mL (3.5) Whole Blood EDTA (Pink Top) Room Temperature Alternate 7 mL (3.5) Whole Blood EDTA (Lavender Top) Room Temperature GENERAL INFORMATION Testing Schedule: Daily Expected TAT: 1 Day Clinical Use: Used to determine the patient's blood type. Notes: Extended Rh typing, Du typing, will be performed on all women of child bearing age. Cpt Code(s): 86900; 86901 COPYRIGHT REGIONAL MEDICAL LABORATORY 2013: VISIT US ONLINE AT: www.rmlonline.com REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: ABORHN ABORh Newborn Test Number: 7301020 TEST COMPONENTS REV DATE: 10/28/2011 Test Name: Methodology: Anti-A HA Anti-B HA Anti-A,B HA Anti-D HA Du HA ABO Rh Interpretation HA SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 2 mL (1) Cord Blood No Additive Clot (Red Top, No-Gel, Plastic) Room Temperature Alternate 2 mL (1) Whole Blood EDTA (Lavender) Microtainer/Bullet Room Temperature GENERAL INFORMATION Testing Schedule: Daily Expected TAT: 1 day Clinical Use: Used to determine the patient's blood type Notes: For forward blood typing in patients less than 3 months old. Cpt Code(s): 86900, 86091 Order Name: ACETAMIN Acetaminophen Quantitative Test Number: 4000050 TEST COMPONENTS REV DATE: 11/12/2003 Test Name: Methodology: Acetaminophen Quantitative CEDIA SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 1 mL (0.5) Plasma Lithium Heparin PST (Light Green Top) Refrigerated Alternate 1 mL (0.5) Serum Clot Activator SST (Red/Gray or Tiger Top) Refrigerated Special Specimen stability: Ambient 8 hours. Refrigerated 7 days. Instructions: GENERAL INFORMATION Testing Schedule: Daily Expected TAT: 1-2 days Clinical Use: Useful for monitoring toxicity in overdose cases. Cpt Code(s): 82003 COPYRIGHT REGIONAL MEDICAL LABORATORY 2013: VISIT US ONLINE AT: www.rmlonline.com REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: ACETAM SC Acetaminophen Screen Serum Test Number: 4302050 TEST COMPONENTS REV DATE: 05/12/2010 Test Name: Methodology: Acetaminophen Screen Serum CEDIA SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 1 mL (0.5) Serum Clot Activator (Red Top, No-Gel) Refrigerated Special Recommended collection time is four hours after an oral dose. Instructions: Stability: Room temperature:8hrs. Refrigerated:7days. GENERAL INFORMATION Testing Schedule: Daily Expected TAT: 1-2 days Clinical Use: Useful for monitoring toxicity in overdose cases. Cpt Code(s): 80101 Order Name: ACETY BND Acetylcholine Receptor Binding Antibody Test Number: 5500010 TEST COMPONENTS REV DATE: 08/15/2011 Test Name: Methodology: Acetylcholine Receptor Binding Antibody RIA SPECIMEN REQUIREMENTS Specimen Specimen Type Specimen Container Transport Volume(min) Environment Preferred 1 mL (0.5) Serum Clot Activator (Red Top, No-Gel) Refrigerated Alternate 1 mL (0.5) Serum Clot Activator SST (Red/Gray or Tiger Top) Refrigerated Special SST Clot tubes acceptable, however it is best if collected in non-gel clot tubes. Specimen stability: Room temperature: 2 hours; Instructions: Refrigerated: 2 weeks; Frozen: 1 year. GENERAL INFORMATION Testing Schedule: Sun-Sat Expected TAT: 4-5 Days Clinical Use: Used to aid in the differential diagnosis of myasthenia gravis-like muscle weakness, in differentiating between generalized MG and ocular MG, and in monitoring therapeutic response. Cpt Code(s): 83519 COPYRIGHT REGIONAL MEDICAL LABORATORY 2013: VISIT US ONLINE AT: www.rmlonline.com REGIONAL MEDICAL LABORATORY 1923 SOUTH UTICA AVENUE TULSA, OKLAHOMA 74104-6502 Order Name: ACETY BLK Acetylcholine Receptor Blocking Antibody Test Number: 5500020 TEST COMPONENTS REV DATE:
Load more

Recommended publications
  • 1970Qureshiocr.Pdf (10.44Mb)
    STUDY INVOLVING METABOLISM OF 17-KETOSTEROIDS AND 17-HYDROXYCORTICOSTEROIDS OF HEALTHY YOUNG MEN DURING AMBULATION AND RECUMBENCY A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN NUTRITION IN THE GRADUATE DIVISION OF THE TEXAS WOI\IIAN 'S UNIVERSITY COLLEGE OF HOUSEHOLD ARTS AND SCIENCES BY SANOBER QURESHI I B .Sc. I M.S. DENTON I TEXAS MAY I 1970 ACKNOWLEDGMENTS The author wishes to express her sincere gratitude to those who assisted her with her research problem and with the preparation of this dissertation. To Dr. Pauline Beery Mack, Director of the Texas Woman's University Research Institute, for her invaluable assistance and gui­ dance during the author's entire graduate program, and for help in the preparation of this dissertation; To the National Aeronautics and Space Administration for their support of the research project of which the author's study is a part; To Dr. Elsa A. Dozier for directing the author's s tucly during 1969, and to Dr. Kathryn Montgomery beginning in early 1970, for serving as the immeclia te director of the author while she was working on the completion of the investic;ation and the preparation of this dis- sertation; To Dr. Jessie Bateman, Dean of the College of Household Arts and Sciences, for her assistance in all aspects of the author's graduate program; iii To Dr. Ralph Pyke and Mr. Walter Gilchrist 1 for their ass is­ tance and generous kindness while the author's research program was in progress; To Mr. Eugene Van Hooser 1 for help during various parts of her research program; To Dr.
    [Show full text]
  • 18-Dehydrogenase Deficiency W
    Arch Dis Child: first published as 10.1136/adc.51.8.576 on 1 August 1976. Downloaded from Archives of Disease in Childhood, 1976, 51, 576. Hypoaldosteronism in three sibs due to 18-dehydrogenase deficiency W. HAMILTON, A. E. McCANDLESS, J. T. IRELAND, and C. E. GRAY From the University Departments of Child Health, Liverpool and Glasgow Hamilton, W., McCandless, A. E., Ireland, J. T., and Gray, C. E. (1976). Archives of Disease in Childhood, 51, 576. Hypoaldosteronism in three sibs due to 18-dehydrogenase deficiency. Three sibs all presented in the early neonatal period with a salt-losing syndrome. The salt-losing form of congenital adrenal hyperplasia was diagnosed and appropriate treatment with glucocorticosteroids, mineralocorticosteroids, and additional dietary salt started. Although early life was maintained with difficulty, with age all3 children required decreasingamounts ofreplace- ment steroids to maintain normal plasma electrolyte balance. They were reinvestigated at the ages of 15 years and 8 years (twins), when cortisol synthesis and metabolism proved normal, but aldosterone synthesis was blocked by deficiency of 18-dehydro- genase. Rational treatment of these cases of a salt-losing syndrome in which aldo- sterone synthesis alone is blocked due to lack of the enzyme 18-dehydrogenase requires the administration of a mineralocorticosteroid drug only. Since deoxycor- ticosterone (acetate or pivalate) requires intramuscular administration, as life-long therapy oral fludrocortisone is preferable. Although fludrocortisone has glucocorti- coid activity, the 'hydrocortisone equivalent' effect of the small dosage used was un- likely to inhibit either pituitary corticotrophin or growth hormone production. Salt-loss of adrenal origin is recognized as a female external genitalia or macrogenitosomia http://adc.bmj.com/ feature of 3/1-hydroxysteroid dehydrogenase de- praecox in the male.
    [Show full text]
  • Robust Extraction, Separation, and Quantitation of Structural Isomer Steroids from Human Plasma by SPE-UHPLC-MS/MS
    TECHNICAL NOTE 21882 Robust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS Authors Application benefits Jon Bardsley1, Kean Woodmansey1, • Separation of structural isomers for accurate detection and Stacy Tremintin2 • Alternative selectivity to C18 phase with an increase in overall resolution of 1Thermo Fisher Scientific, Runcorn, structural isomers UK; 2Thermo Fisher Scientific, Sunnyvale, CA, USA • Stable retention time from extracted plasma • Accurate and precise analytical method across 1000-fold concentration Keywords range Steroid hormone, Vanquish Horizon UHPLC, TSQ Quantiva, Accucore Goal Biphenyl column, LC-MS/MS, SPE Achieve separation of 12 steroid hormones including structural isomers. Comparison to more popular C18 phase is assessed, as well as extraction from human plasma using polymeric solid phase extraction. Introduction Accurate measurement of steroids in plasma is an important requirement in clinical research laboratories. Triple quadrupole mass spectrometry (MS/MS) is now a standard platform in this area for detection due to speed and sensitivity, however this group of compounds contains many structural isomers that cannot be differentiated by MS/MS alone. This may lead to inaccurate analysis by over estimation of concentration levels. Separation prior to MS/MS detection must be achieved, typically by liquid chromatography (LC). An analytical method utilizing LC-MS/MS combined with solid phase extraction of plasma samples is used to remove many matrix interferences,
    [Show full text]
  • Internal Hcpcs Code Description Charge Charge Number Lab 10001 84060 Acid Phosphatase #829642 68.5 10002 82040 Albumin Sera 69.5
    INTERNAL HCPCS CODE DESCRIPTION CHARGE CHARGE NUMBER LAB 10001 84060 ACID PHOSPHATASE #829642 68.5 10002 82040 ALBUMIN SERA 69.5 10003 84075 ALKALINE PHOSPHATASE 52.5 10004 82150 AMYLASE 7 80.5 10009 82088 ALDOSTERONE, SERUM #004374 498 10011 86060 ASO TITER #006031 119.5 10013 84600 ALCOHOL, METHYL #017699 219 10014 87116 AFB CULTURE AND SMEAR/ #183753 165 10015 86901 BLOOD TYPING-RH (D) 23 10016 87206 ACID FAST STAIN #008618 73 10017 82247 TOTAL BILIRUBIN 50.5 10018 86900 BLOOD TYPING-ABO 23 10019 85002 BLEEDING TIME 50.5 10020 84520 BUN 43.5 10022 82607 VITAMIN B-12 115 10026 82310 CALCIUM,TOTAL 39 10027 85025 CBC W/COMP DIFF 69.5 10028 82380 CAROTENE #001529 138.5 10029 82435 CHLORIDE SERUM 80.5 10030 82465 CHOLESTEROL 50.5 10032 82550 CPK, TOTAL 67.5 10033 82565 CREATININE 44.5 10034 82575 CREATININE CLEARANCE #003004 80.5 10035 82378 CEA #002139 169 10036 87070 CULTURE SPUTUM & GRAM STAIN 51.5 10037 82552 CPK ISOENZYMES #002154 123.5 10038 82355 CALCULUS ANALYSIS #120790 142 10039 82382 CATECHOLAMINES,RANDOM URINE #316203 179.5 10040 82533 CORTISOL,TOTAL 175.5 10041 85007 DIFFERENTIAL 22 10044 80162 DIGOXIN/LANOXIN LEVEL 152 10045 80185 DILANTIN, QUANT 105.5 10048 P9016 PRBC'S 326.5 10050 36430 BLOOD ADMINISTRATION 262.5 10051 86022 PLATELETS APHERESIS 1112 10054 83700 ELECTROPHORESIS, LIPOPROTEIN #235036 165 10055 83020 ELECTROPHORESIS, HEMOGLOBIN 82.5 10056 80307 ETHANOL, QUANT. 173.5 10057 87106 FUNGAL ID #390 167 10058 86780 FTA-ABS #006379 118 10059 82746 FOLATE (FOLIC ACID) SERUM 68.5 10062 82941 GASTRIN SERUM #004390 95.5 10063 87205 GRAM STAIN 42 10064 85014 HCT 28 10065 85018 HEMOGLOBIN 28 10066 84702 HCG, QUANT.
    [Show full text]
  • Medicine, St. Louis, Mo.) 17-Hydroxycorticosteroids Of
    BINDING OF CORTICOSTEROIDS BY PLASMA PROTEINS. III. THE BINDING OF CORTICOSTEROID AND RELATED HORMONES BY HUMAN PLASMA AND PLASMA PROTEIN FRAC- TIONS AS MEASURED BY EQUILIBRIUM DIALYSIS 1, 2 BY WILLIAM H. DAUGHADAY WITH THE TECHNICAL ASSISTANCE OF IDA KOZAK (From the Metabolism Dizision, Department of Medicine, Washington University School of Medicine, St. Louis, Mo.) (Submitted for publication September 30, 1957; accepted December 5, 1957) The physical state of the corticosteroid hor- drawn, although little loss of binding affinity occurred mones in human plasma has been under investi- after storage at -10° C. The conditions of dialysis were the same as previously reported (2). Usually 10 ml. of gation in this laboratory. Dialysis equilibrium ex- plasma in a cellophane bag (Visking nojax, 18/32 casing) periments have been reported which show that the was dialyzed against 40 ml. of Krebs phosphosaline buf- 17-hydroxycorticosteroids of plasma are bound to fer, pH 7.4 (4), in a large test tube. Where a high de- plasma proteins to an extent of more than 90 per gree of binding was anticipated, 80 ml. of buffer was cent (2). Of the plasma protein fractions tested used. In several experiments where the amount of plasma or plasma protein fraction was limited, 5 ml. of protein for their cortisol binding power with high con- solution was dialyzed against 40 ml. of buffer. The ra- centrations of cortisol, albumin had the greatest dioactive and nonradioactive steroids were included in binding affinity. The importance of albumin was the dialysis buffer by diluting an alcoholic solution of apparently further supported by equilibrium pa- the steroids with buffer.
    [Show full text]
  • Medical Record Requirements for Pre-Service Reviews
    Medical Record Requirements for Pre-Service Reviews This document lists medical record requirements for pre-service reviews. These requirements are developed using the clinical criteria in UnitedHealthcare medical policies in conjunction with the guidance provided by UnitedHealthcare physicians and pharmacists with experience in reviewing pre-service requests for coverage. These medical record requirements were developed in an effort to decrease the need for repeated requests for additional information and to improve turnaround time for coverage decisions. Please prepare the suggested materials in advance. We reserve the right to request more information, if necessary. Medical record requirements for case review(s) may vary among various UnitedHealthcare Commercial, UnitedHealthcare Community Plan and UnitedHealthcare Medicare Advantage benefit plans. Please review the requirements for notifications and prior authorization requests at UHCprovider.com/priorauth. These medical record requirements are provided for reference purposes only and may not include all services or codes. Listing of a service or code in this document does not imply that it is a covered or non-covered health service or code. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws. This document is the property of UnitedHealthcare and unauthorized copying, use or distribution of this information is strictly prohibited. It is regularly reviewed, updated and subject to change. Click a service category from the Table of Contents to jump to the applicable section of this document. Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc. Page 1 of 141 Table of Contents Click a service category below to jump to the applicable section of this document.
    [Show full text]
  • Parotid Fluid Cortisol and Cortisone
    Parotid Fluid Cortisol and Cortisone FRED H. KAIZ and IRA L. SHANNON From the Department of Medicine, Loyola University Stritch School of Medicine, Hines, Illinois 60141 and the Section of Experimental Dentistry, U. S. Air Force School of Aerospace Medicine, Brooks Air Force Base, Texas 78235 A B S T R A C T Parotid fluid corticosteroids, substan- parallels that of plasma after the administration of tially comprised of cortisol and cortisone, were previ- ACTH (1). Parotid fluid-Porter-Silber chromogens are ously demonstrated to rise to far greater levels 4 hr af- also a useful index to adrenocortical suppression by dexa- ter administration of ACTH than they did in the third methasone1 (2) and for the diagnosis of Cushing's trimester of pregnancy, although the plasma total corti- syndrome (3). During pregnancy, despite a two- to costeroid concentrations were similar in these two threefold increase in plasma 17-hydroxycorticosteroids, states. It was therefore suggested that only nonprotein- the parotid fluid corticosteroids rose only minimally bound corticosteroid gains access to parotid fluid. In though significantly (4). Following ACTH treatment, the present study parotid fluid cortisol and cortisone and when plasma corticosteroids were similar to the values plasma dialyzable cortisol concentrations have been found in pregnant women, the parotid fluid corticoids measured in normal men before and 2 hr after 40 U rose to values several times the base line. Because most ACTH, and, in another group, before and after 10 days of the increased plasma 17-hydroxycorticosteroids in of diethystilbestrol (5 mg daily). Total plasma cortisol pregnancy are protein-bound, whereas the acute increase rose from a mean of 6.3 to 17.9 ,ug/100 ml after ACTH following ACTH represents more nonprotein-bound and from 14.6 to 39.4 mg/100 ml after the estrogen.
    [Show full text]
  • Progesterone and 17 Α-Hydroxyprogesterone: Novel Stimulators of Calcium Influx in Human Sperm Peter F
    Old Dominion University ODU Digital Commons Bioelectrics Publications Frank Reidy Research Center for Bioelectrics 1990 Progesterone and 17 α-Hydroxyprogesterone: Novel Stimulators of Calcium Influx in Human Sperm Peter F. Blackmore Stephen J. Beebe Old Dominion University, [email protected] Douglas R. Danforth Nancy Alexander Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs Part of the Cell and Developmental Biology Commons, Molecular Biology Commons, Reproductive and Urinary Physiology Commons, and the Structural Biology Commons Repository Citation Blackmore, Peter F.; Beebe, Stephen J.; Danforth, Douglas R.; and Alexander, Nancy, "Progesterone and 17 α-Hydroxyprogesterone: Novel Stimulators of Calcium Influx in Human Sperm" (1990). Bioelectrics Publications. 78. https://digitalcommons.odu.edu/bioelectrics_pubs/78 Original Publication Citation Blackmore, P.F., Beebe, S.J., Danforth, D.R., & Alexander, N. (1990). Progesterone and 17 α-hydroxyprogesterone: Novel stimulators of calcium influx in human sperm. Journal of Biological Chemistry, 265(3), 1376-1380. This Article is brought to you for free and open access by the Frank Reidy Research Center for Bioelectrics at ODU Digital Commons. It has been accepted for inclusion in Bioelectrics Publications by an authorized administrator of ODU Digital Commons. For more information, please contact [email protected]. THE JOURNAL OF B~OLOCXCAL CHEMISTRY Vol. 265, No. 3, Issue of January 25, pp. 1376-1380,199O 0 1990 by The American Society for Biochemistry and Molecular Biolow, Inc Printed in U. S. A. Progesterone and 17wHydroxyprogesterone NOVEL STIMULATORS OF CALCIUM INFLUX IN HUMAN SPERM* (Received for publication, August 21, 1989) Peter F. BlackmoreS& Stephen J. Beeben, Douglas R. Danforthn, and Nancy Alexanderll From the Departments of SPharmacology and IlObstetrics and Gynecology and the Jones Institute, Eastern Virginia Medical School, Norfolk, Virginia 23501 Progesterone and 17a-hydroxyprogesterone (but not reaction (AR)’ in human (e.g.
    [Show full text]
  • Current and Novel Approaches to Children and Young People with Congenital Adrenal Hyperplasia and Adrenal Insufficiency Webb, Emma A.; Krone, Nils
    University of Birmingham Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency Webb, Emma A.; Krone, Nils DOI: 10.1016/j.beem.2015.04.002 License: Other (please specify with Rights Statement) Document Version Peer reviewed version Citation for published version (Harvard): Webb, EA & Krone, N 2015, 'Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency', Best practice & research. Clinical endocrinology & metabolism. https://doi.org/10.1016/j.beem.2015.04.002 Link to publication on Research at Birmingham portal Publisher Rights Statement: NOTICE: this is the author’s version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Webb EA, Krone N, Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency, Best Practice & Research Clinical Endocrinology & Metabolism (2015), doi: 10.1016/j.beem.2015.04.002. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
    [Show full text]
  • Dehydroepiandrosterone: a Potential Therapeutic Agent in the Treatment
    Bentley et al. Burns & Trauma (2019) 7:26 https://doi.org/10.1186/s41038-019-0158-z REVIEW Open Access Dehydroepiandrosterone: a potential therapeutic agent in the treatment and rehabilitation of the traumatically injured patient Conor Bentley1,2,3* , Jon Hazeldine1,3, Carolyn Greig2,4, Janet Lord1,3,4 and Mark Foster1,5 Abstract Severe injuries are the major cause of death in those aged under 40, mainly due to road traffic collisions. Endocrine, metabolic and immune pathways respond to limit the tissue damage sustained and initiate wound healing, repair and regeneration mechanisms. However, depending on age and sex, the response to injury and patient prognosis differ significantly. Glucocorticoids are catabolic and immunosuppressive and are produced as part of the stress response to injury leading to an intra-adrenal shift in steroid biosynthesis at the expense of the anabolic and immune enhancing steroid hormone dehydroepiandrosterone (DHEA) and its sulphated metabolite dehydroepiandrosterone sulphate (DHEAS). The balance of these steroids after injury appears to influence outcomes in injured humans, with high cortisol: DHEAS ratio associated with increased morbidity and mortality. Animal models of trauma, sepsis, wound healing, neuroprotection and burns have all shown a reduction in pro- inflammatory cytokines, improved survival and increased resistance to pathological challenges with DHEA supplementation. Human supplementation studies, which have focused on post-menopausal females, older adults, or adrenal insufficiency have shown that restoring the cortisol: DHEAS ratio improves wound healing, mood, bone remodelling and psychological well-being. Currently, there are no DHEA or DHEAS supplementation studies in trauma patients, but we review here the evidence for this potential therapeutic agent in the treatment and rehabilitation of the severely injured patient.
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Endocrine Test Selection and Interpretation
    The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition The Quest Diagnostics Manual Endocrinology Test Selection and Interpretation Fourth Edition Edited by: Delbert A. Fisher, MD Senior Science Officer Quest Diagnostics Nichols Institute Professor Emeritus, Pediatrics and Medicine UCLA School of Medicine Consulting Editors: Wael Salameh, MD, FACP Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute San Juan Capistrano, CA Associate Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Richard W. Furlanetto, MD, PhD Medical Director, Endocrinology/Metabolism Quest Diagnostics Nichols Institute Chantilly, VA ©2007 Quest Diagnostics Incorporated. All rights reserved. Fourth Edition Printed in the United States of America Quest, Quest Diagnostics, the associated logo, Nichols Institute, and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. All third party marks − ®' and ™' − are the property of their respective owners. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, and information storage and retrieval system, without permission in writing from the publisher. Address inquiries to the Medical Information Department, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130. Previous editions copyrighted in 1996, 1998, and 2004. Re-order # IG1984 Forward Quest Diagnostics Nichols Institute has been
    [Show full text]